Corium International Company Profile (NASDAQ:CORI)

About Corium International (NASDAQ:CORI)

Corium International logoCorium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CORI
  • CUSIP: N/A
  • Web:
  • Market Cap: $349.92 million
  • Outstanding Shares: 35,742,000
Average Prices:
  • 50 Day Moving Avg: $10.04
  • 200 Day Moving Avg: $7.59
  • 52 Week Range: $2.67 - $11.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.38
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $30.34 million
  • Price / Sales: 12.09
  • Book Value: $0.77 per share
  • Price / Book: 13.32
  • EBITDA: ($34,210,000.00)
  • Net Margins: -145.60%
  • Return on Equity: -673.17%
  • Return on Assets: -61.19%
  • Debt-to-Equity Ratio: 1.89%
  • Current Ratio: 7.04%
  • Quick Ratio: 6.80%
  • Average Volume: 157,527 shs.
  • Beta: 1.24
  • Short Ratio: 8.51

Frequently Asked Questions for Corium International (NASDAQ:CORI)

What is Corium International's stock symbol?

Corium International trades on the NASDAQ under the ticker symbol "CORI."

How were Corium International's earnings last quarter?

Corium International, Inc. (NASDAQ:CORI) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The business had revenue of $8.11 million for the quarter, compared to analyst estimates of $8.71 million. Corium International had a negative return on equity of 673.17% and a negative net margin of 145.60%. View Corium International's Earnings History.

Where is Corium International's stock going? Where will Corium International's stock price be in 2017?

7 brokers have issued 12-month price targets for Corium International's stock. Their predictions range from $10.00 to $16.00. On average, they anticipate Corium International's stock price to reach $13.14 in the next twelve months. View Analyst Ratings for Corium International.

What are analysts saying about Corium International stock?

Here are some recent quotes from research analysts about Corium International stock:

  • 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (10/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "CORI continues to make progress on the donepezil patch, which we believe could be an important new Alzheimer’s therapy with pivotal top-line data that demonstrate bioequivalence and reduced GI side effects." (9/27/2017)
  • 3. Jefferies Group LLC analysts commented, "CORI posted a slightly narrower than expected loss (-$10.4M vs -$11.2M JEF). Key pipeline product donepezil TD finished the 2nd of three stages of the pilot study and remains on track to start the pivotal Ph 3 study in 2H17. Partners P&G and AGRX continue to support the topline but a new partnership remains key for FY17 in order for mgt to remain credible and generate much needed non-dilutive financing." (2/15/2017)
  • 4. Needham & Company LLC analysts commented, "CORI reported FY1Q17 financials and provided a development update for its Alzheimer's disease transdermal patch programs. The second treatment period of the ongoing pilot BE study for the donepezil patch recently completed and the first interim results are expected in March. The upcoming interim look could provide the initial derisking for the Corplex CNS patch program. CORI recently completed a $20MM equity raise that extends the cash runway into late-2017/ early-2018. We maintain our Buy rating and adjust our $PT to $10 (from $12) to reflect the new higher share count and expected volatility in revenues from partnered products." (2/14/2017)
  • 5. FBR & Co analysts commented, "Corium reported below-consensus revenue and EPS after the market close on November 21. While EPS and revenues were disappointing in the quarter, we believe that investors should continue to focus on the company’s impressive CNS patch pipeline. Corium has received favorable written feedback from the FDA regarding its development of Corplex donepezil and Corplex memantine. The FDA has indicated that if Corium can demonstrate bioequivalence between its products and oral Aricept (donepezil) and oral Namenda XR (memantine) in bioequivalence (BE) studies, then it could submit a 505(b)(2) NDA without conducting additional clinical efficacy trials. We believe meaningful catalysts are ahead in 2017. Patient dosing started in September for a pilot study for Corplex donepezil in preparation for the pivotal BE trial in 2H17." (11/22/2016)

Who are some of Corium International's key competitors?

Who are Corium International's key executives?

Corium International's management team includes the folowing people:

  • David L. Greenwood, Chairman of the Board
  • Peter D. Staple, President, Chief Executive Officer, Director
  • Robert S. Breuil, Chief Financial Officer
  • Parminder Singh Ph.D., Chief Technology Officer, Vice President - Research & Development
  • Joseph J. Sarret M.D. J.D., Chief Business Officer
  • Robert W. Thomas, Lead Independent Director
  • Eric H. Bjerkholt, Independent Director
  • Bhaskar Michael Chaudhuri Ph.D., Independent Director
  • Ronald W. Eastman, Independent Director
  • Phyllis I. Gardner M.D., Independent Director

How do I buy Corium International stock?

Shares of Corium International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corium International's stock price today?

One share of Corium International stock can currently be purchased for approximately $10.26.

MarketBeat Community Rating for Corium International (NASDAQ CORI)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Corium International (NASDAQ:CORI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.14 (28.10% upside)
Consensus Price Target History for Corium International (NASDAQ:CORI)
Price Target History for Corium International (NASDAQ:CORI)
Analysts' Ratings History for Corium International (NASDAQ:CORI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/27/2017Cantor FitzgeraldReiterated RatingBuy$12.00HighView Rating Details
9/26/2017HC WainwrightInitiated CoverageBuy -> Buy$15.00MediumView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$13.00MediumView Rating Details
8/7/2017Jefferies Group LLCReiterated RatingBuy -> Buy$8.00 -> $10.00LowView Rating Details
7/7/2017WBB SecuritiesUpgradeBuy$13.00LowView Rating Details
4/18/2017FBR & CoReiterated RatingOutperform -> Outperform$12.00 -> $13.00LowView Rating Details
1/4/2017Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Corium International (NASDAQ:CORI)
Earnings by Quarter for Corium International (NASDAQ:CORI)
Earnings History by Quarter for Corium International (NASDAQ CORI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q3 2017($0.30)($0.43)$8.71 million$8.11 millionViewListenView Earnings Details
5/11/2017Q2 2017($0.37)($0.42)$6.05 million$7.35 millionViewN/AView Earnings Details
2/13/2017Q1 2017($0.42)($0.46)$8.07 million$7.00 millionViewN/AView Earnings Details
11/21/2016Q4 2016($0.39)($0.42)$9.08 million$7.92 millionViewN/AView Earnings Details
8/4/2016Q3($0.42)($0.34)$8.38 million$10.61 millionViewN/AView Earnings Details
5/10/2016Q2($0.37)($0.47)$8.64 million$6.96 millionViewListenView Earnings Details
2/8/2016Q1($0.35)($0.42)$8.93 million$7.54 millionViewN/AView Earnings Details
11/12/2015Q4($0.45)($0.42)$9.47 million$9.27 millionViewListenView Earnings Details
7/29/2015Q3($0.37)($0.33)$10.45 million$10.60 millionViewListenView Earnings Details
2/10/2015Q115($0.29)($0.37)$10.42 million$9.77 millionViewN/AView Earnings Details
11/17/2014Q4 2014($0.32)($0.51)$10.26 million$11.07 millionViewN/AView Earnings Details
8/12/2014Q3 2014($0.17)($0.28)$12.22 million$10.18 millionViewN/AView Earnings Details
5/13/2014Q2 2014($0.18)($0.24)$10.58 million$10.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Corium International (NASDAQ:CORI)
2017 EPS Consensus Estimate: ($1.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.50)($0.39)($0.43)
Q2 20173($0.44)($0.36)($0.39)
Q3 20173($0.41)($0.24)($0.34)
Q4 20173($0.49)($0.27)($0.40)
(Data provided by Zacks Investment Research)


Dividend History for Corium International (NASDAQ:CORI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Corium International (NASDAQ:CORI)
Insider Ownership Percentage: 45.70%
Institutional Ownership Percentage: 90.14%
Insider Trades by Quarter for Corium International (NASDAQ:CORI)
Institutional Ownership by Quarter for Corium International (NASDAQ:CORI)
Insider Trades by Quarter for Corium International (NASDAQ:CORI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2017Healthcare Master Fun BroadfinMajor ShareholderSell218,100$11.01$2,401,281.00View SEC Filing  
8/22/2017Parminder SinghInsiderSell30,415$7.59$230,849.85View SEC Filing  
8/17/2017Parminder SinghInsiderSell32,000$7.61$243,520.00View SEC Filing  
8/17/2017Timothy D. SweemerCAOSell12,012$7.62$91,531.44View SEC Filing  
8/16/2017Timothy D. SweemerCAOSell15,488$7.82$121,116.16View SEC Filing  
7/20/2017Joseph J. SarretInsiderSell2,038$8.95$18,240.10View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy301,004$7.71$2,320,740.84View SEC Filing  
5/25/2017Perceptive Advisors LlcMajor ShareholderBuy1,902,400$6.25$11,890,000.00View SEC Filing  
5/19/2016Eric BjerkholtDirectorBuy24,500$3.64$89,180.00View SEC Filing  
5/12/2016David GreenwoodDirectorBuy3,000$3.58$10,740.00View SEC Filing  
2/25/2015Peter D StapleCEOBuy3,600$6.99$25,164.00View SEC Filing  
11/24/2014Robert S BreuilCFOBuy4,600$5.38$24,748.00View SEC Filing  
11/21/2014Peter D StapleCEOBuy9,000$5.34$48,060.00View SEC Filing  
8/27/2014Peter D StapleCEOBuy2,578$6.10$15,725.80View SEC Filing  
5/30/2014Peter D StapleCEOBuy7,200$7.04$50,688.00View SEC Filing  
4/8/2014Woodlands Health Venture EssexMajor ShareholderBuy400,000$8.00$3,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Corium International (NASDAQ:CORI)
Latest Headlines for Corium International (NASDAQ:CORI)
DateHeadline logoETFs with exposure to Corium International, Inc. : October 16, 2017 - October 16 at 6:12 PM logoZacks Investment Research Downgrades Corium International, Inc. (CORI) to Sell - October 11 at 12:38 AM logoHealthcare Master Fun Broadfin Sells 218,100 Shares of Corium International, Inc. (CORI) Stock - October 6 at 7:24 PM logo$9.57 Million in Sales Expected for Corium International, Inc. (CORI) This Quarter - October 6 at 5:14 AM logoCorium International, Inc. :CORI-US: Earnings Analysis: Q3, 2017 By the Numbers : September 29, 2017 - October 3 at 5:20 AM logoCorium International, Inc. (CORI) Earns Buy Rating from Cantor Fitzgerald - October 1 at 5:52 PM logoHC Wainwright Initiates Coverage on Corium International, Inc. (CORI) - September 26 at 7:24 AM logoCorium International, Inc. (CORI) Given Consensus Recommendation of "Buy" by Brokerages - September 23 at 8:50 PM logoCorium International, Inc. (CORI) Receives Buy Rating from Needham & Company LLC - September 17 at 8:58 AM logoCorium to Present at Upcoming Healthcare Conferences - September 5 at 7:02 PM logoCritical Contrast: Corium International (CORI) versus BioLife Solutions (BLFS) - September 4 at 8:20 PM logoCorium International, Inc. (CORI) Receives Consensus Rating of "Buy" from Brokerages - August 29 at 9:14 PM logoAequus Announces Abbreviated Development Path for Transdermal Aripiprazole - August 24 at 5:36 PM logoCorium International, Inc. (CORI) Insider Sells $230,849.85 in Stock - August 24 at 4:20 AM logoForm 4 Corium International, For: Aug 23 Filed by: STAPLE PETER D - August 24 at 4:06 AM logoWorld Vaccine Delivery Devices Market 2014-2017 & 2025 - Market is Expected to Reach USD 6.21 Billion - August 18 at 10:29 PM logoInsider Selling: Corium International, Inc. (CORI) CAO Sells 15,488 Shares of Stock - August 18 at 10:28 PM logoCorium International, Inc. (CORI) CAO Sells $91,531.44 in Stock - August 18 at 10:28 PM logoParminder Singh Sells 32,000 Shares of Corium International, Inc. (CORI) Stock - August 18 at 10:28 PM logoFY2017 Earnings Forecast for Corium International, Inc. Issued By Cantor Fitzgerald (NASDAQ:CORI) - August 10 at 1:50 PM logoCorium International, Inc. (NASDAQ:CORI) Forecasted to Post FY2017 Earnings of ($1.81) Per Share - August 9 at 8:54 AM logoCorium International's (CORI) "Buy" Rating Reiterated at Jefferies Group LLC - August 7 at 10:14 AM logoCorium International Inc (CORI) Given Average Rating of "Buy" by Analysts - August 4 at 8:44 PM logoCorium International Inc (CORI) Issues Quarterly Earnings Results - August 4 at 7:30 PM logoEdited Transcript of CORI earnings conference call or presentation 3-Aug-17 9:00pm GMT - August 4 at 5:42 PM logoCorium reports 3Q loss - August 3 at 11:57 PM logoInvestor Network: Corium International, Inc. to Host Earnings Call - August 3 at 6:53 PM logoCorium Reports Recent Corporate Highlights and Financial Results for Third Quarter Fiscal 2017 - August 3 at 6:53 PM logoCorium to Report Third Quarter Fiscal 2017 Financial Results on Thursday, August 3, 2017 - July 27 at 5:44 PM logoVaccine Delivery Devices Market Size Worth $6.21 Billion by 2025: Grand View Research, Inc. - July 25 at 10:25 PM logo$8.47 Million in Sales Expected for Corium International, Inc. (CORI) This Quarter - July 22 at 8:50 AM logoJoseph J. Sarret Sells 2,038 Shares of Corium International, Inc. (CORI) Stock - July 22 at 7:22 AM logoCorium International, Inc. (NASDAQ:CORI) Receives "Buy" Rating from Jefferies Group LLC - July 19 at 8:52 AM logoCorium Internation (CORI) Presents Results from Pilot Bioequivalence Study of Corplex Donepezil Transdermal System at AAIC - July 19 at 5:00 AM logoBRIEF-Corium presents clinical results from pilot bioequivalence study - July 19 at 5:00 AM logoCorium Presents Clinical Results from Pilot Bioequivalence Study of Corplex™ Donepezil Transdermal System at Alzheimer's Association International Conference® 2017 - July 18 at 6:57 PM logoShort Interest in Corium International, Inc. (NASDAQ:CORI) Increases By 62.3% - July 16 at 7:06 AM logoCorium International, Inc. (NASDAQ:CORI) Receives Average Rating of "Buy" from Analysts - July 10 at 8:30 PM logoCorium International, Inc. (CORI) Upgraded by WBB Securities to Buy - July 7 at 10:58 AM logoCorium to Present Clinical Results from Pilot Bioequivalence Study of Once-weekly Corplex™ Donepezil Transdermal System at Alzheimer's Association International Conference® 2017 - July 6 at 6:43 PM logoInsider Buying: Corium International, Inc. (CORI) Major Shareholder Buys 301,004 Shares of Stock - July 5 at 7:07 PM logoCorium Hopes Stock Offering Will Firm Its Footing In Pharma Partner Talks - May 25 at 12:16 PM logoCorium International, Inc. 2017 Q2 - Results - Earnings Call Slides - May 14 at 4:32 PM logoBRIEF-Corium reports positive preliminary results in Alzheimer’s clinical study - May 12 at 9:57 PM logoBRIEF-RTW Investments reports 5 pct passive stake in Corium International - May 5 at 9:41 PM logoCorium International Has A New Take On A Great Drug - May 2 at 4:32 PM logoBRIEF-Corium International says entered supply agreement with Procter & Gamble Manufacturing Co - May 1 at 8:26 AM logoCorium International (CORI) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 9:07 AM logoCorium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex™ Donepezil Patch - March 20 at 4:25 PM logoCorium International, Inc. :CORI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 20, 2017 - March 20 at 4:25 PM



Corium International (CORI) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.